Comprehensive Assessment of PCSK9 Inhibitors for Lipid Management: Scientific Guidance Based on Drug Selection Recommendations for Chinese Medical Institutions.

IF 4.7 2区医学 Q1 CHEMISTRY, MEDICINAL Drug Design, Development and Therapy Pub Date : 2024-12-27 eCollection Date: 2024-01-01 DOI:10.2147/DDDT.S493912

Jiabao Li, Siyong Huang, Xiao Hu, Jisheng Chen

{"title":"Comprehensive Assessment of PCSK9 Inhibitors for Lipid Management: Scientific Guidance Based on Drug Selection Recommendations for Chinese Medical Institutions.","authors":"Jiabao Li, Siyong Huang, Xiao Hu, Jisheng Chen","doi":"10.2147/DDDT.S493912","DOIUrl":null,"url":null,"abstract":"Objective: This study aims to support the selection of PCSK9 inhibitors for patients requiring lipid management within medical institutions. By quantitatively evaluating four PCSK9 inhibitors, we provide evidence-based guidance for optimal selection in this patient population.Methods: According to the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition) released in 2023, relevant databases such as PubMed, Cochrane, Embase, drug labels, and clinical guidelines were searched for drug information. Using a percentage scoring method, we systematically evaluated 4 PCSK9 inhibitors marketed in China for safety, efficacy, economy, pharmacological properties, and other attributes.Results: The final assessment result scores from highest to lowest were evolocumab (78.00 points), alirocumab (77.24 points), inclisiran (72.89 points), and tafolecimab (65.33 points). Evolocumab was the best in the economy, alirocumab scored the highest in terms of efficacy and other attributes, and inclisiran had the strongest performance in terms of pharmacological properties.Conclusion: For lipid management in medical institutions, evolocumab, alirocumab, inclisiran, and tafolecimab may be prioritized accordingly based on evaluation results.","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"18 ","pages":"6297-6312"},"PeriodicalIF":4.7000,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11687099/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S493912","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aims to support the selection of PCSK9 inhibitors for patients requiring lipid management within medical institutions. By quantitatively evaluating four PCSK9 inhibitors, we provide evidence-based guidance for optimal selection in this patient population.

Methods: According to the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition) released in 2023, relevant databases such as PubMed, Cochrane, Embase, drug labels, and clinical guidelines were searched for drug information. Using a percentage scoring method, we systematically evaluated 4 PCSK9 inhibitors marketed in China for safety, efficacy, economy, pharmacological properties, and other attributes.

Results: The final assessment result scores from highest to lowest were evolocumab (78.00 points), alirocumab (77.24 points), inclisiran (72.89 points), and tafolecimab (65.33 points). Evolocumab was the best in the economy, alirocumab scored the highest in terms of efficacy and other attributes, and inclisiran had the strongest performance in terms of pharmacological properties.

Conclusion: For lipid management in medical institutions, evolocumab, alirocumab, inclisiran, and tafolecimab may be prioritized accordingly based on evaluation results.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

PCSK9抑制剂对血脂管理的综合评价：基于中国医疗机构药物选择建议的科学指导

目的：本研究旨在为医疗机构内需要脂质管理的患者选择PCSK9抑制剂提供支持。通过定量评估四种PCSK9抑制剂，我们为该患者群体的最佳选择提供循证指导。方法：根据2023年发布的《中国医疗机构药品评价与选择快速指南（第二版）》，检索PubMed、Cochrane、Embase、药品标签、临床指南等相关数据库进行药物信息检索。采用百分比评分法，我们系统地评估了在中国上市的4种PCSK9抑制剂的安全性、有效性、经济性、药理学性质和其他属性。结果：最终评估结果评分从高到低依次为evolocumab（78.00分）、alirocumab（77.24分）、inclisiran（72.89分）、tafolecimab（65.33分）。Evolocumab在经济性方面是最好的，alirocumab在疗效和其他属性方面得分最高，而inclisiran在药理学特性方面表现最强。结论：对于医疗机构的脂质管理，根据评价结果，evolocumab、alirocumab、inclisiran、tafolecimab可相应优先使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY

CiteScore

9.00

自引率

0.00%

发文量

382

审稿时长

>12 weeks

期刊介绍： Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.